Several randomized, placebocontrolled clini cal trials (RCTs) have been conducted over the
last 20 years enrolling more than 15,000 patients in total to evaluate the survival benefit …

More than two dozen well-designed, randomized, controlled phase II or III clinical trials,
published over the past 15 years, have tested the hypothesis that modulating the host …

Several clinical trials have attempted to treat sepsis by blocking certain aspects of the
inflammatory response. Tumor necrosis factor and interleukin 1 have been specific targets …

It is a phrase that has become painfully familiar, intoned not only in the ivory towers of
academia but equally in the biotech boardrooms. In the last 10 years, approximately 20 …

The pathophysiology of sepsis has been studied intensively in recent years and a variety of
opportunities for therapeutic intervention have been identified. A number of biological …

Perhaps no clinical problem lacking effective therapy has been as extensively studied as
sepsis. A MEDLINE search under the MESH heading,“sepsis”, currently yields more than …

Sepsis is the clinical manifestation of the host-derived systemic inflammatory response
resulting from invasive infection. Sepsis begins with a nidus of infection, frequently gram …

Sepsis remains one of the leading causes of mortality in critically ill patients. Increased
insight into the complexities of this disease process has resulted in the targeting of various …

A prevailing hypothesis is that at low levels cytokines perform important homeostatic actions
that regulate immunologic and physiologic events. At higher concentrations, cytokines can …

Sepsis–the most common cause of death in hospitalized patients–affects over 18 million
people worldwide and has an expected 1% increase of incidence per year. Recent clinical …